These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 17604412)

  • 21. Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods.
    Montastruc JL; Sommet A; Lacroix I; Olivier P; Durrieu G; Damase-Michel C; Lapeyre-Mestre M; Bagheri H
    Joint Bone Spine; 2006 Dec; 73(6):629-32. PubMed ID: 17110152
    [No Abstract]   [Full Text] [Related]  

  • 22. Signal detection activity on EudraVigilance data: analysis of the procedure and findings from an Italian Regional Centre for Pharmacovigilance.
    Monaco L; Melis M; Biagi C; Donati M; Sapigni E; Vaccheri A; Motola D
    Expert Opin Drug Saf; 2017 Mar; 16(3):271-275. PubMed ID: 28094583
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Signal selection and follow-up in pharmacovigilance.
    Meyboom RH; Lindquist M; Egberts AC; Edwards IR
    Drug Saf; 2002; 25(6):459-65. PubMed ID: 12071784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An Evaluation of Indian Consumers' Reporting of Suspected Adverse Drug Reactions with a Designated Reporting Form.
    Rehan HS; Sah R; Gupta A; Nagar P
    Curr Drug Saf; 2017; 12(1):51-56. PubMed ID: 27188794
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prescription-event monitoring: developments in signal detection.
    Ferreira G
    Drug Saf; 2007; 30(7):639-41. PubMed ID: 17604421
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Under-reporting of adverse drug reactions: a challenge for pharmacovigilance in India.
    Tandon VR; Mahajan V; Khajuria V; Gillani Z
    Indian J Pharmacol; 2015; 47(1):65-71. PubMed ID: 25821314
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of exposure misclassification in spontaneous ADR reports on the time to detection of product-specific risks for biologicals: a simulation study.
    Vermeer NS; Ebbers HC; Straus SM; Leufkens HG; Egberts TC; De Bruin ML
    Pharmacoepidemiol Drug Saf; 2016 Mar; 25(3):297-306. PubMed ID: 26676881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early identification of adverse drug reactions from search log data.
    White RW; Wang S; Pant A; Harpaz R; Shukla P; Sun W; DuMouchel W; Horvitz E
    J Biomed Inform; 2016 Feb; 59():42-8. PubMed ID: 26610385
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Safety of medicinal products and reporting of adverse drug reactions].
    Skibicka I; Maciejczyk A
    Neurol Neurochir Pol; 2004; 38(6):503-10. PubMed ID: 15654675
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structured assessment for prospective identification of safety signals in electronic medical records: evaluation in the health improvement network.
    Cederholm S; Hill G; Asiimwe A; Bate A; Bhayat F; Persson Brobert G; Bergvall T; Ansell D; Star K; Norén GN
    Drug Saf; 2015 Jan; 38(1):87-100. PubMed ID: 25539877
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potential use of data-mining algorithms for the detection of 'surprise' adverse drug reactions.
    Hauben M; Horn S; Reich L
    Drug Saf; 2007; 30(2):143-55. PubMed ID: 17253879
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Towards on-line ADR detection: an innovative data cube-based approach.
    Lin WY; Du JW
    Stud Health Technol Inform; 2013; 192():1218. PubMed ID: 23920992
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A survey of spontaneous reporting of adverse drug reactions in 10 years of activity in a pharmacovigilance centre in Portugal.
    Marques J; Ribeiro-Vaz I; Pereira AC; Polónia J
    Int J Pharm Pract; 2014 Aug; 22(4):275-82. PubMed ID: 24188533
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Principles of data mining.
    Hand DJ
    Drug Saf; 2007; 30(7):621-2. PubMed ID: 17604416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Veterinary pharmacovigilance in India: A need of hour.
    Kumar R; Kalaiselvan V; Verma R; Kaur I; Kumar P; Singh GN
    Indian J Pharmacol; 2017; 49(1):2-3. PubMed ID: 28458414
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database.
    Szarfman A; Machado SG; O'Neill RT
    Drug Saf; 2002; 25(6):381-92. PubMed ID: 12071774
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decision support methods for the detection of adverse events in post-marketing data.
    Hauben M; Bate A
    Drug Discov Today; 2009 Apr; 14(7-8):343-57. PubMed ID: 19187799
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety of fibrinogen concentrate: analysis of more than 27 years of pharmacovigilance data.
    Solomon C; Gröner A; Ye J; Pendrak I
    Thromb Haemost; 2015 Apr; 113(4):759-71. PubMed ID: 25502954
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Analysis of Spontaneously Reported Adverse Events].
    Nakamura M
    Yakugaku Zasshi; 2016; 136(4):549-56. PubMed ID: 27040337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.